Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.

December 22, 2017

Tremeau and FDA Agree on Phase 3 Plan to Test Rofecoxib in Hemophilia Joint Pain

News

Tremeau Pharmaceuticals has received guidance from the U.S. Food and Drug Administration (FDA) on how to conduct a pivotal Phase 3 trial exploring rofecoxib (TRM-201) in patients with hemophilia-associated joint ... Read more

December 13, 2017

Gene Therapy Nearly Eliminates Hemophilia B Bleeding Episodes, Trial Shows

News

A hemophilia gene therapy developed by Spark Therapeutics and Pfizer nearly eliminated bleeding episodes in 10 patients who took part in a Phase 1/2 trial. The treatment, SPK-9001, worked so well in eight ... Read more

August 21, 2017August 28, 2017

Spark’s Gene Therapies to Treat Hemophilia A and B Advance in Clinical Trials

News

Three patients who received SPK-8011 — a gene therapy developed by Spark Therapeutics — for hemophilia A show increased production of clotting factor VIII without any safety issues reported, says ... Read more

July 26, 2017July 26, 2017

EU Grants €5.6 Million to Consortium Developing Sernova’s Cell Pouch Therapy for Hemophilia A Patients

News

The European Commission will award the Brussels-based HemAcure Consortium €5.6 million in next-stage funding of a therapy called Cell Pouch — developed in collaboration with Canada’s Sernova — for hemophilia A patients. The therapy delivers ... Read more

July 17, 2017July 17, 2017

CSL Behring’s Afstyla Allows Hemophilia A Patients to Use Less Factor Replacement, Analysis Shows

News

Hemophilia A patients treated with CSL Behring’s Afstyla (recombinant factor 8 single-chain) require less factor to control bleeding compared to those taking octocog alfa, the company recently announced. The lower ... Read more

April 12, 2017

Aptevo’s Ixinity Found Safe, Effective in Kids Under 12 with Hemophilia B, Trial Shows

News

Ixinity (recombinant factor IX product, IB1001) was found to be safe and effective in previously treated children with hemophilia B younger than 12, according to data from Aptevo Therapeutics‘ ongoing ... Read more

April 3, 2017

Improvements in Gene Therapy Carriers Key Step in Hemophilia Treatment Development

News

Although gene therapy for hemophilia has reached clinical testing in humans, researchers continue to work toward improved delivery systems of the treatment — not an easy task considering the large size ... Read more

March 22, 2017March 22, 2017

Hemophilia B Hurts Education, Job Prospects for Both Adult Patients and Caregivers, Study Finds

News

Hemophilia B hurts educational and job prospects for both adults with the disease and caregivers of hemophiliac children, a recent study found. The study, “Impact of mild to severe hemophilia ... Read more

March 10, 2017

Zepatier Found Effective, Safe Against Hepatitis C in Hemophilia Patients

News

Zepatier (elbasvir/grazoprevir) is an effective and safe treatment for hepatitis C infection in hemophilia patients and others with inherited blood disorders — a group that has been particularly exposed to such ... Read more

February 22, 2017

Distress Triggers Brain Changes in Hemophilia Children, Study Suggests

News

Psychological distress triggers microscopic changes in regions of hemophiliac children’s brains that deal with emotions and cognition — and the changes show up before abnormal results on neuropsychiatric tests, researchers discovered. ... Read more